Market News & Trends
ContraVir Pharmaceuticals Announces Completion of Phase 1 With CRV431
ContraVir Pharmaceuticals, Inc. recently announced that the primary endpoints of safety and tolerability were met in a single ascending dose (SAD) study of CRV431 conducted…
Neurimmune Achieves Milestone in Collaboration With Ono Pharmaceutical
Neurimmune recently announced the achievement of a key preclinical milestone in the ongoing collaboration with Ono Pharmaceutical Co., Ltd. In November 2017, the parties entered…
Lonza Launches Early-Intermediates Supply Initiative for Small-Molecule APIs
Lonza Pharma & Biotech recently announced the launch of its pharmaceutical early-intermediates supply initiative. The initiative leverages chemical production facilities at the company’s Visp (CH)…
Beta Bionics Secures $50-Million Financing for Bionic Pancreas
Beta Bionics, Inc. recently announced it has so far raised $50 million of a Series B equity financing. The round was led by Eventide Asset Management,…
Thermo Fisher Scientific to Launch Global Customer Solution Centers
Thermo Fisher Scientific Inc. recently announced its intent to open multiple Global Customer Solution Centers. The new Global Customer Solution Centers will focus on meeting and exceeding the demands of scientists in food, beverage, pharmaceutical and biotech laboratories by developing critical workflows and integrated solutions that help advance chromatography and mass spectrometry worldwide.
Molecular Templates Announces Agreement With Takeda for Joint Development of Protein-Based Oncology Therapy
Molecular Templates, Inc. recently announced an agreement with Takeda Pharmaceutical Company Limited for the joint development of CD38-targeted engineered toxin bodies (ETBs) for the treatment of patients with diseases such as multiple myeloma.
Evonik Completes Multi-Million Dollar Expansion of its CMO Capabilities for API & Advanced Intermediates
Evonik, a global CMO leader for API and advanced intermediates, recently announced the completion of a 36-million euro expansion of its contract manufacturing capabilities in the US and Europe.
PCI Pharma Services Announces Agreement to Acquire Sherpa Clinical Packaging
PCI Pharma Services recently announced the acquisition of San Diego-based Sherpa Clinical Packaging, which expands PCI’s US operations to the West Coast. The acquisition of…
SAMDI Tech Increases Clients’ Opportunities for Drug Candidate Hit Finding With Charles River Partnership
SAMDI Tech, Inc., the industry’s leading provider of label-free drug discovery solutions, has partnered with Charles River Laboratories, which provides products and services that accelerate…
IMV Announces Phase 2 Basket Trial in Collaboration With Merck
IMV Inc. recently announced it has expanded its clinical program with a Phase 2 basket trial evaluating its lead candidate, DPX-Survivac, in combination with low-…
Telix Completes Acquisition of Atlab for Prostate Cancer Program
Telix Pharmaceuticals Limited recently announced completion of the acquisition of Atlab Pharma SAS. The option to acquire Atlab for the consideration of $10 million (in…
Dalton Pharma Services Invests in Fully Automated Sterile Liquid Filling System
As a part of a $10-million dollar facility and capital expansion, Dalton Pharma Services, a leading North American contract research, development & manufacturing organization, has…
Pfanstiehl Launches New cGMP-Produced, Parenteral-Grade Arginine for Biopharmaceutical & Pharmaceutical Formulations
As Pfanstiehl approaches its 100th anniversary in 2019, the company has launched a new high purity, low endotoxin, and low metal L-Arginine (USP, EP, JP,…
VistaGen Therapeutics Acquires Worldwide License of Phase 3-Ready CNS Drug Candidate
VistaGen Therapeutics, Inc. and Pherin Pharmaceuticals, Inc. recently announced the signing of a license agreement granting VistaGen exclusive worldwide rights to develop and commercialize PH94B nasal spray, a Phase 3-ready drug candidate for as-needed (PRN) treatment of Social Anxiety Disorder (SAD).
PAREXEL Advances Patient-Centric Drug Development With Introduction of its Patient Innovation Center
PAREXEL International Corporation, a leading innovator of global biopharmaceutical services, today announced the launch of its Patient Innovation Center, designed to help guide sponsors in their efforts to improve efficiency and success across all areas of biopharmaceutical development including clinical trial design, recruitment, execution and market access.
Sandoz & Teva Have Potential to Transform Epinephrine Injection Market
With no generic versions and few comparable alternatives, Mylan’s EpiPen has dominated the epinephrine injection device market for over a decade. However, this summer has…
Inoviem Scientific Enters Into Service-Based Partnership With XoNovo
Inoviem Scientific recently announced a service-based partnership with XoNovo, a preclinical-stage biopharmaceutical company developing a proprietary small molecule for the treatment of neurodegenerative diseases. Financial…
Opiant Pharmaceuticals Announces Final Patient Enrolled in Phase 2 Clinical Trial
Opiant Pharmaceuticals, Inc. recently announced it has completed patient enrollment in its Phase 2 clinical trial of OPTN001, a naloxone nasal spray, for the treatment…
Pieris Pharmaceuticals Announces Dosing of First Patient in Phase I Combination Trial
Pieris Pharmaceuticals, Inc. recently announced it has dosed the first patient in the company’s Phase 1 combination clinical trial of PRS-343, its lead proprietary immuno-oncology…
MilliporeSigma Launches Next-Generation Process Technologies for Intensified Drug Production
MilliporeSigma recently launched three new products to help biomanufacturers navigate the evolving biopharma landscape with increased speed, greater flexibility, and enhanced quality. These next-generation process…
